Pregled bibliografske jedinice broj: 1156245
Konkomitantna kemobrahiradioterapija s ifosfamidom i cisplatinom praćeno konsolidacijskom kemoterapijom kod žena s lokalno uznapredovalim rakom grlića maternice-završni rezultati prospektivne studije faze II
Konkomitantna kemobrahiradioterapija s ifosfamidom i cisplatinom praćeno konsolidacijskom kemoterapijom kod žena s lokalno uznapredovalim rakom grlića maternice-završni rezultati prospektivne studije faze II // Gynecologic oncology, 103 (2006), 2; 494-499 doi:10.1016/j.ygyno.2006.03.06 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1156245 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Konkomitantna kemobrahiradioterapija s ifosfamidom i cisplatinom praćeno konsolidacijskom kemoterapijom kod žena s lokalno uznapredovalim rakom grlića maternice-završni rezultati prospektivne studije faze II
(Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy for women with locally advanced carcinoma of the uterine cervix-final results of a prospective phase II-study)
Autori
Vrdoljak Eduard, Omrčen Tomislav, Novaković Žana Saratlija, Jelavić Tihana Boraska, Prskalo Tomislav, Hrepić Darijo, Hamm Wolfgang
Izvornik
Gynecologic oncology (0090-8258) 103
(2006), 2;
494-499
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Rak glića maternice, kemobrahiradioterapija, cisplatin, ifosfamid
(Cervical carcinoma ; Chemobrachyradiotherapy ; Cisplatin ; Ifosfamide)
Sažetak
Objectives. To evaluate the efficacy and toxicity of ifosfamide and cisplatin administered concomitantly with low-dose rate brachyradiotherapy followed by consolidation chemotherapy in the treatment of locally advanced squamous cell carcinoma (LASCC) or adeno/adenosquamous carcinoma of the uterine cervix. Methods. Sixty-two patients with primary uterine cervical cancer were enrolled between August 1999 and November 2004. The patients had to have FIGO-stage IB2 bulky to IVA disease, biopsy-proven squamous cell or adeno/adenosquamous carcinoma of the uterine cervix. The patients were to receive external radiotherapy (50 Gy in 25 fractions) ; ifosfamide 2 g/m2 plus cisplatin 75 mg/m2 was applied concomitantly during two low-dose rate brachyradiotherapy applications ; the planned dose to point A was 85 Gy in total. After the completion of radiotherapy, i.e. external and concomitant chemobrachyradiotherapy, four cycles of consolidation chemotherapy with the same drug combination were to be administered. Results. The clinical complete response rate according to WHO-classification (assessed after the completion of the whole treatment procedures by gynecologic and radiologic evaluation and cervical biopsy) was 100%. After a median follow-up of 49 months (range 11–74 months), the recurrence-free and overall survival rates were 88.7%, respectively. The most frequent early toxicities were grade 3 and 4 leukopenias occurring in 25% and 11% of the cycles, respectively. Major delayed local complications occurred in 10 patients (16.1%). Conclusion. These results indicate that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is a highly efficacious and very promising treatment protocol for patients with locally advanced LASCC or adeno/adenosquamous carcinoma of the uterine cervix
Izvorni jezik
Engleski
Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE